To test this hypothesis in liver cancer cell lines, siRNA‐mediated Gli1 and Gli3 knockdown, as well as activation of the signalling pathway using SHH treatment and the combination treatment of CD90 knockdown with SHH treatment, were carried out in the present study. The gene discussed is THY1; the disease is liver cancer.